Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.

By ··1 min read·4 sources

The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.

The statute makes it a crime to pay a doctor to induce a prescription. It does not ban an honorarium for a talk about the drug, so long as the program is presented as education. In a U.S. market worth about $907 billion in 2025, speaker fees keep doctors loyal to drugmakers. One review found speakers with disclosed conflicts three to six times more likely to give favorable testimony.

Pfizer's record is why the question matters. In 2009 it paid $2.3 billion to resolve federal allegations of off-label promotion and kickbacks on Bextra and other drugs. It later proposed paying Medicare patients' Vyndamax copays directly, and the Second Circuit held that would be an unlawful inducement. The price that plan would have shielded is now $23,560.57 for a 30-capsule pack, about $283,000 a year, by Pfizer's own July 2026 disclosure to Connecticut.

Rivals have their own conflicts. Clinics can profit from buying and billing an injected drug such as Alnylam's Amvuttra instead of prescribing a pill. That does not excuse the oral incumbent. Whatever Pfizer pays physicians in connection with Vyndamax sits in a federal payments database, not in anything a patient sees in the consulting room. A company with this settlement history should have to show those payments are education and not reward.

Sources

  1. technology.org · technology.org/2026/09/14/speaker-fees-and-buy-and-bill-keep-doctors-loyal-to-pharma/
  2. justice.gov · justice.gov/archives/opa/pr/justice-department-announces-largest-health-care-fraud-settlem…
  3. cdn.pfizer.com · cdn.pfizer.com/pfizercom/products/ctprescribers/VYNDAMAXCTPriceDisclosureShortForm07062026…
  4. ibtimes.com · ibtimes.com/some-treatments-are-more-profitable-others-3806517

Cite this report

The Precedent. "Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.." September 24, 2026. https://theprecedent.org/article/pfizer-paid-23-billion-over-kickbacks-then-asked-to-pay-vyndamax-patients-copays

Companies in this report